Contents lists available at ScienceDirect

Dermatologica Sinica

journal homepage: http://www.derm-sinica.com

ORIGINAL ARTICLE

Association between insulin resistance and serum and salivary irisin levels in patients with psoriasis vulgaris[☆]

Emine Tugba Alatas [1, *], Mehmet Kalayci [2], Asude Kara [3], Gursoy Dogan [1]

[1] Department of Dermatology, Mugla Sitki Kocman University Faculty of Medicine, Mugla, Turkey
[2] Department of Biochemistry Elazig Training and Research Hospital, Elazıg, Turkey
[3] Department of Dermatology, Mugla Sitki Kocman University Training and Research Hospital, Mugla, Turkey

ARTICLE INFO

ABSTRACT

Background/Objectives: Psoriasis is an inflammatory skin disease, which is associated with metabolic syndrome and insulin resistance. Irisin is an adipokine and myokine that regulates the metabolic status during times of increased insulin sensitivity. In this study, we aimed to investigate changes in the serum level of irisin in psoriasis patients in comparison with participants who did not have any disease (control group). We hope the results of our study would also aid in establishing a protocol aimed at understanding the etiopathogenesis and treatment of psoriasis.
Materials and methods: The study included 30 patients with psoriasis vulgaris, who presented to the dermatology outpatient clinic and were not receiving systemic treatment. The control group included voluntary participants who did not have any disease ($n = 30$). In addition to venous and salivary irisin levels, glucose, triglyceride, cholesterol, high-density lipoprotein, and low-density lipoprotein levels, and Homeostasis Model Assessment of Insulin Resistance scores were measured in both control and patient groups.
Results: Serum irisin and salivary irisin levels were significantly lower in the patient group compared with the control group ($p < 0.05$). In the patient group, serum irisin levels had a positive correlation with salivary irisin levels ($r = 418$; $p = 0.022$) and a negative correlation with Psoriasis Area and Severity Index ($r = -437$, $p = 0.016$) and Dermatological Life Quality Index ($r = -424$; $p = 0.02$) scores.
Conclusion: This is the first study evaluating irisin levels in patients with psoriasis vulgaris in the literature. The results of our study show that serum and salivary irisin levels were significantly lower in the patient group when compared with the control group. Irisin levels in patients with severe psoriasis were low, suggesting that irisin may have a role in the pathogenesis of psoriasis and may be a marker showing the severity of psoriasis, which could warn us against the development of insulin resistance and diabetes mellitus.

Introduction

Psoriasis is a chronic, hyperproliferative inflammatory disease of the skin, which is clinically characterized by erythematous and squamous plaques. The disease is associated with a genetic background.[1] Because of the silvery, scaly appearance of the squamous plaques, in Turkish it is called "nacre disease" in layman's terms.[2,3] Psoriasis is observed in 1–3% of the general population.[4]

Irisin, first discovered by Bostrom et al, is made up of 112 amino acids.[5] It is an adipokine and myokine, and exhibits autocrine and paracrine effects. Irisin is mainly synthesized in skeletal muscle and adipose tissue.[5] Furthermore, irisin predominantly presents in peripheral nerve cells, sebaceous glands of the skin, as well as in many organs and tissues.[6] It induces the conversion of white adipose tissue into brown adipose tissue. In addition, it regulates thermogenesis, energy expenditure, weight loss, and ultimately glucose homeostasis by increasing uncoupling protein 1 in brown adipose

tissue.[6] Irisin, also called "exercise hormone," is produced by the cleavage of fibronectin type III domain-containing protein 5 (FNDC5), the extracellular portion of type I membrane protein, following activation by peroxisome proliferator-activated receptor-γ coactivator α.[6] Proteins associated with insulin resistance, such as adiponectin and ghrelin, are known to play a role in the pathogenesis of psoriasis.[7] Irisin is also a hormone associated with obesity and glucose homeostasis. Patients with type 2 diabetes mellitus (DM) have low levels of irisin. Moreover, irisin level has been found to be decreased in nonalcoholic fatty liver disease and heart failure.[8]

The association between psoriasis and insulin resistance is known, and many studies in have been published in this area.[9,10] However, none of these studies has evaluated irisin levels in patients with psoriasis. Our study is the first study to examine irisin levels in psoriasis aimed at understanding etiopathogenesis of the disease. In our study, by measuring irisin levels in patients with psoriasis, which is a disease associated with increased insulin resistance, we evaluated whether irisin levels show any correlation with severity of the disease. We hope our results would also aid in establishing a protocol aimed at understanding the etiopathogenesis and treatment of psoriasis.

Materials and methods

This study was conducted by the Dermatology Department of Mugla Sitki Kocman University Faculty of Medicine. The study included patients diagnosed with psoriasis vulgaris ($n = 30$), who presented to the dermatology outpatient clinic and were not receiving systemic treatment (receiving topical therapy). The control group included voluntary participants who did not have any disease ($n = 30$). Individuals in both groups were informed about the study protocol, and all participants provided written consent.

The study exclusion criteria were as follows: (1) other forms of psoriasis such as pustular psoriasis or erythrodermic psoriasis; (2) presence of any systemic disease (coronary artery disease, hepatic failure, renal failure, malignancy, etc.); (3) pregnancy; (4) breastfeeding; (5) younger than 18 years of age; and (6) receiving systemic treatment.

All participants provided a detailed history. Age, duration of disease, presence of any other family member with psoriasis, smoking status, and current treatment methods were questioned and noted on patient forms. Extent and severity of psoriasis were assessed using the Psoriasis Area and Severity Index (PASI) scoring method and by calculating the affected body surface area percentage.

Individuals in both the patient and control groups provided 3 mL of venous blood and 0.5 mL of saliva samples following 8−12 hours of fasting. Saliva samples were collected in sterile urine cups. Blood and saliva samples were centrifuged at 4000 rpm for 10 minutes. The samples were then transferred to small-volume tubes, and stored at −80°C until further analysis. Irisin levels were analyzed using enzyme linked-immunosorbent assay. In addition to venous and salivary irisin levels, we also measured glucose, triglyceride, cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein levels in both patient and control groups. Insulin resistance was calculated according to the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) formula: fasting glucose (mmol/L) × fasting serum insulin (μIU/mL)/ 22.5. In addition, body mass index (BMI) and Dermatological Life Quality Index (DLQI) values were calculated.

Comparison of parameters between the two groups were made with Kolmogorov−Smirnov test and Student t test. Correlation of parameters were analyzed with Spearman correlation test and p values less than 0.05 was accepted as the level of significance.

Results

There were 15 males (50%) and 15 females (50%) in the patient group, and 15 males (50%) and 15 females (50%) in the control group. There was no statistically significant difference between the two groups in distribution of sex ($p > 0.05$). Mean age was 39.67 ± 9.30 years in the patient group, whereas it was 39.76 ± 15.74 years in the control group. Mean BMI was 27.73 ± 4.17 kg/m^2 in the patient group, and 26.17 ± 3.81 kg/m^2 in the control group. There was no statistically significant difference between the patient and control groups regarding mean age and BMI ($p > 0.05$). PASI scores in the patient group varied between 0.4 and 15.8, and the mean PASI score was 4.71 ± 3.52. The DLQI value in the patient group varied between 0 and 26. The mean DLQI value was 10.73 ± 7.82. Table 1 summarizes biochemical parameters, insulin and hemoglobin A1c (HbA1c) levels, and HOMA-IR scores in the patient and control groups.

Serum irisin and salivary irisin levels were significantly lower in the patient group when compared with the control group ($p < 0.05$; Figure 1).

The patient group had significantly higher serum glucose and triglyceride levels, and significantly lower HDL levels when compared with the control group ($p < 0.05$; Figure 2).

The patient group had significantly higher HbA1c levels and HOMA-IR scores when compared with the control group ($p < 0.05$; Figure 3).

In the patient group, serum irisin levels showed a positive correlation with salivary irisin levels ($r = 418$; $p = 0.022$) and a negative correlation with PASI ($r = -437$; $p = 0.016$) and DLQI ($r = -424$; $p = 0.02$) values. Salivary irisin levels had a negative correlation with PASI, but these correlations were not statistically significant ($r = -351$; $p = 0.058$). In addition, serum irisin levels had a negative correlation with serum triglyceride levels and HOMA-IR scores and a positive correlation with serum HDL levels; however, these correlations were also not statistically significant.

Discussion

Although the pathogenesis of psoriasis is not fully understood, activation of T lymphocytes and keratinocyte hyperproliferation are given particular emphasis in pathogenesis. In addition, there is evidence indicating a role of endothelial cells in pathogenesis in the early period of psoriasis. The most commonly emphasized mechanism concerning pathogenesis of psoriasis involves activation of T cells of the immune system. Activated T cells release cytokines such as interferon-γ or tumor necrosis factor-α (TNF-α), and increase concentration of other immune effector cells, including neutrophils, in the inflammation site.[11] TNF-α additionally stimulates vascular endothelial cell growth factor production in keratinocytes, and induces secondary proliferation of epidermal and vascular cells.[12] Various studies have been performed to determine the pathogenesis of psoriasis; however, its etiology is not yet clear. Many studies have emphasized chronic inflammation in psoriasis.[13,14] Recently, a strong association has been suggested to exist between psoriasis and metabolic syndrome as well as one of its components, insulin resistance.[15,16] It has been suggested that cytokines that are released during the chronic inflammation in psoriasis may lead to the development of metabolic syndrome. One study emphasized the presence of a strong correlation between severity of psoriasis and insulin resistance. Furthermore, it drew attention to psoriasis not only as a disease of the skin, but also as a metabolic disease.[17]

Adipocytes are described as newly introduced members of the immune system, as they release cytokines such as interleukin 6 and TNF-α in addition to adipokines such as irisin, adiponectin, and